A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Inclusion Criteria

• •1. Participants with locally advanced or metastatic breast cancer.
• •2. Participants must have progressed after at least after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an Anthracycline and a Taxane unless participants who are not suitable for these treatments.
• •3. Participants must have documented disease progression within or on 6 months from their last anti-cancer therapy.
• •4. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\<=) 2.
• •5. Participants must have normal organ and marrow function as defined below:
• •* Absolute neutrophil count greater than (\>) 1,500 per microliter (/mcL)
• •* Hemoglobin \>10.0 gram per deciliter (g/dL)
• •* Platelets \>100,000/mcl
• •* Serum total bilirubin less than (\<) 1.5\*upper limit of normal (ULN)
• •* Serum aspartate aminotransferase (AST) (Serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (Serum glutamic pyruvic transaminase \[SGPT\]) \<3\*ULN or \<5\*ULN in the presence of liver metastases
• •* Serum creatinine \<1.5 mg/dL.
• •6. Females in reproductive age willing to follow adequate barrier contraceptive measures during the conduct of study.